Renaissance Capital logo

Research Alliance II Priced, Nasdaq: RACB

Second blank check company formed by RA Capital targeting the biotech industry (liquidated).

Industry: SPAC

Latest Trade: $10.11 0.00 (0.0%)

First Day Return: +2.1%

Return from IPO: +1.1%

Industry: SPAC

We are a newly organized blank check company. While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare industry, with an emphasis on the biotechnology sector where our management has extensive investment experience. Our sponsor is an affiliate of RA Capital, a leading life sciences focused investment firm with over $7 billion of regulatory assets under management as of December 31, 2020. Since its launch in 2002, RA Capital has focused exclusively on the healthcare industry. Peter Kolchinsky, PhD, our founding Chairman and Chief Executive Officer, founded RA Capital, where he is a Managing Partner. Matthew Hammond, PhD, our founding Chief Investment Officer and Director and Tess Cameron, our founding Chief Financial Officer and Director, are Principals on the investment team at RA Capital.
more less
IPO Data
IPO File Date 03/02/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 13.0
Deal Size ($mm) $130
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 03/17/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 13.0
Deal Size ($mm) $130
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Jefferies
Company Data
Headquarters Las Vegas, NV, United States
Founded 2020
Employees 3
Website www.racap.com

Research Alliance II (RACB) Performance